Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
PLUMBERS AND PIPEFITTERS LOCAL 572 HEALTH AND WELFARE FUND v. BIOVAIL CORPORATION et al
Case Number:
2:08-cv-02433
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Ballard Spahr
- Cohen Milstein
- Covington & Burling
- Desmarais LLP
- Gibson Dunn
- Gustafson Gluek
- Hagens Berman
- Herzfeld Suetholz
- Hilliard & Shadowen
- King & Spalding
- Kirkland & Ellis
- Lowey Dannenberg
- Saltz Mongeluzzi
- Stephan Zouras
- Steptoe LLP
- Stranch Jennings
- Troutman Pepper
- Tucker Law Group
- Wexler Boley
Companies
Government Agencies
Sectors & Industries:
-
September 23, 2015
GSK Gets Wellbutrin Pay-For-Delay Antitrust Suit Nixed
A Pennsylvania federal judge nixed claims from consumers and wholesalers Wednesday that GlaxoSmithKline paid off generic rivals to keep cheaper versions of antidepressant Wellbutrin XL off the market, ruling that buyers couldn't show that the settlements that let the patent challenge continue violated antitrust law.
-
August 05, 2015
Decertification Appealed In Wellbutrin Pay-For-Delay Suit
A class of indirect purchasers in the pay-for-delay litigation against GlaxoSmithKline PLC and others over the antidepressant Wellbutrin XL appealed its decertification to the Third Circuit last week after a Pennsylvania federal judge said it hadn't shown the class was ascertainable.
-
June 30, 2015
Indirect Buyers Decertified In Wellbutrin Pay-For-Delay Suit
The Pennsylvania federal judge overseeing pay-for-delay litigation against GlaxoSmithKline PLC and others over the antidepressant Wellbutrin XL decertified the class of indirect purchasers on Tuesday, saying it has failed to carry its burden of showing that the class is ascertainable.
-
February 15, 2013
Valeant Pays $12M To Settle Wellbutrin Antitrust Claims
Valeant Pharmaceuticals International Inc. will pay at least $11.75 million to settle a class action brought by health insurers and other indirect purchasers, accusing it of conspiring to stifle generic versions of antidepressant Wellbutrin XL and monopolize the market, according to documents filed Friday in Pennsylvania federal court.
-
May 11, 2012
GSK, Valeant Dodge Sham Patent Suit Claims In Wellbutrin Row
A Pennsylvania federal judge on Friday granted a move by GlaxoSmithKline PLC and Valeant Pharmaceuticals International to toss claims brought by purchasers of depression medication Wellbutrin XL in an antitrust class action, finding no sham patent suits were brought to delay the drug's generic version.
-
April 11, 2012
Wellbutrin Antitrust Class Survives Bid To Nix Cert.
A class of indirect purchasers of depression medication Wellbutrin XL and its generic equivalent on Monday beat a motion to nix class certification in their antitrust suit accusing GlaxoSmithKline PLC and Valeant Pharmaceuticals International of using sham patent litigation to delay generic competition.
-
May 13, 2010
Aetna Wants To Rep End Payers In Wellbutrin MDL
Aetna Inc. asked a court on Thursday to let it intervene as a class plaintiff on behalf of end payers in the antitrust multidistrict litigation over antidepressant Wellbutrin XL.